Americans For Safe Access – ASA National

Sure enough, patent number 6,630,507 states unequivocally that cannabinoids are useful in the prevention and treatment of a wide variety of diseases including auto-immune disorders, stroke, trauma, Parkinson’s, Alzeheimer’s and HIV dementia. The patent, awarded in 2003, is based on research done by the National Institute of Health, and is assigned to the US Dept. of Health and Human Services.

So, why is this important? Here is a legal document, in the public domain, which flies in the face of the US Government’s stated position with regard to the classification of cannabis as a Schedule I substance having no “currently accepted medical use”. Believe me, citing this patent stops the “medical marijuana is a myth” advocates dead in their tracks. They simply cannot argue with it. The forces that would keep cannabis illegal are vocal and well funded, but they are not impervious to persistent effort. The lynch pin in the War on Drugs is cannabis. Without the suppression and interdiction of this popular and widely used substance, there simply would not be enough “illegal drug use” going on to justify the huge amount of money and resources spent on “fighting drugs.”

Disseminating information about this patent as widely as possible, and to as many people as possible is a crucial strategy in loosening that lynch pin, and changing public perception about cannabis.
Abstract

Other References

• Windholz et al., The Merck Index, Tenth Edition (1983) p. 241, abstract No. 1723.
• Mechoulam et al., “A Total Synthesis of d1-Ɗ¹ -Tetrahydrocannabinol, the Active Constituent of Hashish¹,” Journal of the American Chemical Society, 87:14:3273-3275 (1965)
• Mechoulam et al., “Chemical Basis of Hashish Activity,” Science, 18:611-612 (1970)
• Ottersen et al., “The Crystal and Molecular Structure of Cannabidiol,” Acta Chem. Scand. B 31, 9:807-812 (1977)
• Cunha et al., “Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients¹,” Pharmacology, 21:175-185 (1980)
• Consroe et al., “Acute and Chronic Antiepileptic Drug Effects in Audiogenic Seizure-Susceptible Rats,” Experimental Neurology, Academic Press Inc., 70:626-637 (1980)
• Turkanis et al., “Electrophysiologic Properties of the Cannabinoids,” J. Clin. Pharmacol., 21:449S-463S (1981)
• Carlini et al., “Hypnotic and Antielpileptic Effects of Cannabidiol,” J. Clin. Pharmacol., 21:417S-427S (1981)
• Karler et al., “The Cannabinoids as Potential Antiepileptics,” J. Clin. Pharmacol., 21:437S-448S (1981)
• Consroe et al., “Antiepileptic Potential of Cannabidiol Analgos,” J. Clin. Pharmacol., 21:428S-436S (1981)
• Colasanti et al., “Ocular Hypotension, Ocular Toxicity,a nd Neurotoxicity in Response to Marihuana Extract and Cannabidiol,” Gen Pharm., Pergamon Press Ltd., 15(6):479-484 (1984)
• Colasanti et al., “Intraocular Pressure, Ocular Toxicity and Neurotoxicity after Administration of Cannabinol or Cannabigerol,” Exp. Eye Res., Academic Press Inc., 39:251-259 (1984)
• Volfe et al., “Cannabinoids Block Release of Serotonin from Platelets Induced by Plasma frm Migraine Patients,” Int. J. Clin. Pharm. Res., Bioscience Ediprint Inc., 4:243-246 (1985)
• Agurell et al., “Pharmacokinetics and Metabolism of Ɗ¹ -Tetrahydrocannabinol and Other Cannabinoids with Emphasis on Man*,” Pharmacological Reviews, 38(1):21-43 (1986)
• Karler et al., “Different Cannabinoids Exhibit Different Pharmacological and Toxicological Properties,”NIDA Res. Monogr., 79:96-107 (1987)
• Samara et al., “Pharmacokinetics of Cannabidiol in Dogs,” Drug Metabolism and Disposition, 16(3):469-472 (1988)
• Choi, “Glutamate Neurotoxicity and Diseases of the Nervous System,” Neuron, Cell Press, 1:623-634 (1988)
• Eshhar et al., “Neuroprotective and Antioxidant Activities of HU-211, A Novel NMDA Receptor Antagonist,” European Journal of Pharmacology, 283:19-29 (1995)
• Skaper et al., “The ALIAmide Palmitoylethanolamide and Cannabinoids, but not Anandamide, are Protective in a Delayed Postglutamate Paradigm of Excitotoxic Death in Cerebellar Granule Neurons,” Neurobiology, Proc. Natl. Acad. Sci. USA, 93:3984-3989 (1996)
• Alonso et al., “Simple Synthesis of 5-Substituted Resorcinols: A Revisited Family of Interesting Bioactive Molecules,” J. Org. Chem., American Chemical Society, 62(2):417-421 (1997)
• Combes et al. “A Simple Synthesis of the Natural 2,5-Dialkylresorcinol Free Radical Scavenger Antioxidant: Resorstation,” Synthetic Communications, Marcel Dekker, Inc., 27(21):3769-3778 (1997)
• Shohami et al., “Oxidative Stress in Closed-Head Injury: Brain Antioxidant Capacity as an Indicator of Functional Outcome,” Journal of Cerebral Blood Flow and Metabolism, Lippincott-Raven Publishers, 17(10):1007-1019 (1997)
• Zurier et al., “Dimethylheptyl-THC-11 OIC Acid,” Arthritis & Rheumatism, 41(1):163-170 (1998)
• Hampson et al., “Dual Effects of Anandamide on NMDA Receptor-Mediated Responses and Neurotransmission,” Journal of Neurochemistry, Lippincott-Raven Publishers, 70(2):671-676 (1998)
• Hampson et al., “Cannabidiol and (-)Ɗ⁹ -tetrahydrocannabiono are Neuroprotective Antioxidants,” Medical Sciences, Proc. Natl. Acad. Sci. USA, 8268-8273 (1998)

Medical Marijuana Raids to Continue After House Defeats Defunding Bill